NeuroPace (NPCE) to Release Quarterly Earnings on Thursday

NeuroPace (NASDAQ:NPCE – Get Rating) is set to issue its quarterly earnings data after the market closes on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. NeuroPace has set its FY 2022 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

NeuroPace (NASDAQ:NPCE – Get Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). The company had revenue of $11.37 million for the quarter, compared to analyst estimates of $10.45 million. NeuroPace had a negative net margin of 85.42% and a negative return on equity of 47.77%. On average, analysts expect NeuroPace to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NeuroPace Stock Performance

Shares of NeuroPace stock opened at $5.63 on Thursday. The company has a market cap of $138.53 million, a PE ratio of -3.23 and a beta of 1.54. The company has a quick ratio of 9.48, a current ratio of 10.15 and a debt-to-equity ratio of 0.80. NeuroPace has a 52 week low of $4.61 and a 52 week high of $24.77. The business has a 50 day moving average price of $5.62 and a 200-day moving average price of $7.08.

Institutional Trading of NeuroPace

An institutional investor recently raised its position in NeuroPace stock. State Street Corp grew its stake in shares of NeuroPace, Inc. (NASDAQ:NPCE – Get Rating) by 2.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 98,717 shares of the company’s stock after buying an additional 2,042 shares during the period. State Street Corp owned 0.40% of NeuroPace worth $810,000 at the end of the most recent reporting period. 77.56% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Morgan Stanley dropped their price objective on NeuroPace from $6.00 to $5.50 and set an “underweight” rating on the stock in a research note on Friday, July 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $13.10.

About NeuroPace

(Get Rating)

NeuroPace, Inc operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely.